The Latest Cardiac and Vascular News
MAASTRICHT, Netherlands, May 22, 2018 /PRNewswire/ — A highly innovative software, developed by Pie Medical Imaging – PMI – B.V. (Esaote Group) will be presented at EuroPCR 2018, the world-leading course in interventional cardiovascular medicine, held in Paris, Palais des Congrès (France) between 22 – 25 May 2018. This software – called CAAS vFFR (Cardiovascular Angiographic Analysis Systems for vessel […]
PARIS, May 22, 2018 /PRNewswire/ — NMT2 announces it will be featured at the 2018 EUROPCR Congress in Paris, France. The annual assembly, which again takes place at the Palace de Congress in Paris from May 22-25, 2018, is the worldwide gathering for in-depth scientific presentations, new innovations, training and reports of clinical data results in the […]
WASHINGTON, May 21, 2018 /PRNewswire/ — An article published in Experimental Biology and Medicine (Volume 243, Issue 8, May, 2018) identifies a new approach for treating cardiac arrythmias (http://journals.sagepub.com/doi/full/10.1177/1535370218769420). The study, led by Dr. Congxin Huang, in the Cardiovascular Research Institute at Wuhan University in China, reports that treatment with a β-receptor antagonist abolishes cardiac arrythmias in […]
SAN DIEGO, May 21, 2018 /PRNewswire/ — Viera BioScience announced today positive data demonstrating that its AngioMune™ T Regulatory Cell based product successfully reduced cardiac damage and stimulated production of new blood vessels in animals that were induced to undergo a heart attack. The use of T regulatory cells for angiogenesis is […]
PARIS, May 22, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450 commercial centers around the U.S. show consistently positive patient outcomes. The […]
PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients […]
100 percent technical success and no Major Adverse Cardiac Events (MACE) scored in first pre-clinical randomized trial Rouen, France, May 22, 2018 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, […]
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received […]
First-of-its-Kind Lesion Preparation Tool Fractures Calcium in CAD with Sonic Pressure Waves, Enabling Optimal Stent Delivery and Expansion While Minimizing Trauma First Patient Enrolled in DISRUPT CAD II Post-Market Study Fremont, Calif. — May 21, 2018 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced […]
SHENZHEN, China–(BUSINESS WIRE)–Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd. (Salubris), a multi-national leader in the development and commercialization of cardiovascular products in China and beyond, today announced a strategic investment and in-licensing agreement with Swiss cardiovascular pioneer M.A. MedAlliance S.A. (MedAlliance). Under the terms of the […]
